Pancreatic Neuroendocrine Tumors (PNETS) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Novartis, Ipsen Pharma, Pfizer, Hutchison Medipharma, TaiRx

Pancreatic Neuroendocrine Tumors (PNETS) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Novartis, Ipsen Pharma, Pfizer, Hutchison Medipharma, TaiRx
Delveinsight Business Research LLP
As per DelveInsight, the Pancreatic Neuroendocrine Tumors (PNETS) Market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of PNETs patients in the 7MM, along with the expected entry of improved diagnostic methods such as Octreoscan, and the launch of new therapies in the market.

DelveInsight’s “Pancreatic Neuroendocrine Tumors (PNETS) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pancreatic Neuroendocrine Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Pancreatic Neuroendocrine Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pancreatic Neuroendocrine Tumors treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pancreatic Neuroendocrine Tumors (PNETS): An Overview

According to WHO, Pancreatic neuroendocrine tumors (PNETS) are well differentiated, low, intermediate, or high-grade neuroendocrine neoplasm, which is composed of cells showing minimal to moderate atypia, displaying organoid patterns, lacking necrosis, and expressing general markers of neuroendocrine differentiation (diffuse and intense synaptophysin and usually also chromogranin A staining) and hormones (usually intense but not necessarily diffuse), either orthotopic or ectopic to the pancreas.

The WHO grading system has divided PNET, based on Mitotic count, Ki-67 index to well-differentiated tumors (which includes G1, G2), and poorly differentiated tumors (G3); that have 2- 20 or more mitoses and a Ki-67 index of 3 to 20% or higher, with 5-year survival rate 85% or 9% respectively.

Functional pancreatic NETs include Gastrinoma, Insulinoma, Glucagonoma, and Other types of tumors (VIPomas, which make vasoactive intestinal peptide. VIPoma may also be called Verner-Morrison syndrome, Somatostatinomas, which make somatostatin).

Pancreatic Neuroendocrine Tumors (PNETS) Market Key Facts

  • Among the EU-5 countries, France accounts for the highest market size for Pancreatic Neuroendocrine Tumors, followed by Italy, Germany, Spain, and the UK.

  • Owing to the launch of upcoming therapies and improved diagnostic methods, market size shall increase during the forecast period.

  • Among the 7MM, Japan accounted for 36.07% of the overall market size of Pancreatic Neuroendocrine Tumors in 2017

  • The most prevalent cases of Pancreatic Neuroendocrine Tumors were recorded in Japan.

  • Among the European 5 countries, France had the highest prevalent population of PNETs, followed by Italy and Germany. On the other hand, the United Kingdom had the lowest prevalent population of PNETs.

  • In the stage-wise prevalent cases, Metastatic PNET and regionally advanced PNETs are high in number in comparison to localized or unstaged. The well-differentiated (which includes G1, and G2) are more in comparison to poorly differentiated (G3) tumors.

Pancreatic Neuroendocrine Tumors (PNETS) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Pancreatic Neuroendocrine Tumors pipeline therapies. It also thoroughly assesses the Pancreatic Neuroendocrine Tumors market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Pancreatic Neuroendocrine Tumors drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pancreatic Neuroendocrine Tumors (PNETS) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Pancreatic Neuroendocrine Tumors epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Pancreatic Neuroendocrine Tumors epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Pancreatic Neuroendocrine Tumors Epidemiology, Segmented as –

  • Total Prevalent Cases of PNETs (2019–2032)

  • Functionality-based Prevalence of PNET (2019–2032) 

  • Symptom-based Prevalence of Functional PNET (2019–2032)

  • Grade-wise Prevalence of PNET (2019–2032) 

  • Stage-wise Prevalence of PNET (2019–2032)

  • Gender-specific Prevalence of PNET (2019–2032)

Pancreatic Neuroendocrine Tumors (PNETS) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pancreatic Neuroendocrine Tumors market or expected to be launched during the study period. The analysis covers the Pancreatic Neuroendocrine Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Pancreatic Neuroendocrine Tumors drugs based on their sale and market share.

The report also covers the Pancreatic Neuroendocrine Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Pancreatic Neuroendocrine Tumors companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Pancreatic Neuroendocrine Tumors Market Will Evolve and Grow by 2032 @

Pancreatic Neuroendocrine Tumors (PNETS) Therapeutics Analysis

The treatment landscape of PNET consists of surgical as well as pharmacotherapies. Although surgical therapies occupy the major share to date and are mainly from the first line of defense, but a large section of the patient population presents with advanced disease and are not candidates for resection. In such cases, therapeutic modalities come into play which are primarily symptomatic in nature.

Despite all these available treatment options, the clinical pipeline for PNET seems weak at present, researchers as well as key players such as Hutchinson Medipharma, TaiRx, Inc., and others are actively focused on the development of novel therapies for the treatment of PNET. With the increasing incidence of PNET and their apparent heterogeneity from benign incidental lesions to malignant carcinoma, the management of patients with PNET is complex. This heterogeneity and the multiple effective treatment options have led to the development of a patient-centered, personalized approach to treatment.

Pancreatic Neuroendocrine Tumors (PNETS) Companies Actively Working in the Therapeutics Market Include

  • Advanced Accelerator Applications

  • Ipsen Pharma S.A.S.

  • Pfizer

  • Hutchison Medipharma Limited

  • TaiRx, Inc.

  • Novartis Pharmaceuticals

And Many Others

Emerging and Marketed Pancreatic Neuroendocrine Tumors (PNETS) Therapies Covered in the Report Include:

  • Lutathera: Advanced Accelerator Applications

  • Afinitor: Novartis Pharmaceutical

  • Somatuline Depot: Ipsen Pharma S.A.S.

  • Sutent: Pfizer

  • Surufatinib: Hutchison Medipharma Limited

  • CVM-1118: TaiRx, Inc.

  • PDR001: Novartis Pharmaceuticals

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pancreatic Neuroendocrine Tumors Competitive Intelligence Analysis

4. Pancreatic Neuroendocrine Tumors Market Overview at a Glance

5. Pancreatic Neuroendocrine Tumors Disease Background and Overview

6. Pancreatic Neuroendocrine Tumors Patient Journey

7. Pancreatic Neuroendocrine Tumors Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Pancreatic Neuroendocrine Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Pancreatic Neuroendocrine Tumors Unmet Needs

10. Key Endpoints of Pancreatic Neuroendocrine Tumors Treatment

11. Pancreatic Neuroendocrine Tumors Marketed Therapies

12. Pancreatic Neuroendocrine Tumors Emerging Drugs and Latest Therapeutic Advances

13. Pancreatic Neuroendocrine Tumors Seven Major Market Analysis

14. Attribute Analysis

15. Pancreatic Neuroendocrine Tumors Market Outlook (In US, EU5, and Japan)

16. Pancreatic Neuroendocrine Tumors Companies Active in the Market

17. Pancreatic Neuroendocrine Tumors Access and Reimbursement Overview

18. KOL Views on the Pancreatic Neuroendocrine Tumors Market

19. Pancreatic Neuroendocrine Tumors Market Drivers

20. Pancreatic Neuroendocrine Tumors Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Elevate your business strategy and make informed decisions in a rapidly evolving healthcare landscape, guided by our comprehensive research offerings, at: Healthcare Market Research

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States